Pulse Biosciences
Logotype for Pulse Biosciences Inc

Pulse Biosciences (PLSE) investor relations material

Pulse Biosciences Stifel 2026 Healthcare Conference 2026 summary

Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.
Logotype for Pulse Biosciences Inc
Stifel 2026 Healthcare Conference 2026 summary12 Nov, 2026

Technology and market opportunity

  • nsPFA uses pulse durations 1,000x shorter than microsecond PFA, with higher voltage amplitude; management says the distinct energy creates a different tissue mechanism of action.

  • Issued patents increased by 30, or more than 10%, this year; the platform has a 285-patent portfolio covering waveforms, methods and catheter design.

  • U.S. AF ablation market cited at $4B, with potential to approach $10B in the early 2030s; the market is projected to more than double over 5–7 years.

  • Feasibility workflow averaged 12 five-second applications; management cited faster procedures and potential for 2–3 additional cases per room daily, with $23,000 revenue per case for the service line.

Clinical evidence and regulatory plans

  • Paroxysmal AF feasibility results: 100% freedom from AF off drugs at 6 months, 96% at 12 months, and 90% freedom from all atrial arrhythmias at 12 months.

  • The pivotal paroxysmal AF IDE enrolled its final patient in October, in under 180 days; six-month data were expected by April, with a clinical module submission planned for early Q3 2027.

  • Management expects U.S. approval early in 2028, based on an estimated six-month FDA review; CE mark is expected in H2 2027.

  • A 100-patient, one-year follow-up update is targeted for Q1 at an AF conference; a persistent AF IDE filing is planned for Q4, with study start early the following year.

Pipeline and commercialization

  • A cardiac surgery IDE is enrolling patients with preoperative AF; additional European trials are planned to expand clinical experience.

  • Thyroid nodule treatment targets procedures that may preserve thyroid function; management described a 30–45-minute procedure with same-day discharge.

  • A next-generation catheter is planned to combine regional and focal ablation in one device; mapping integration has been demonstrated with Abbott EnSite X.

  • Management is preparing for a strategic partnership-led commercial approach while retaining the option to operate independently; manufacturing startup investment is beginning ahead of a potential 2028 launch at scale.

  • Cash and marketable securities totaled $189M at the prior quarter-end; management’s goal is to exit the year closer to $200M.

Partial view of Summaries dataset, powered by Quartr API
AI can get things wrong. Verify important information.
Research faster. Power your platform.

Next Pulse Biosciences earnings date

Logotype for Pulse Biosciences Inc
Q4 202618 Mar, 2027
Pulse Biosciences
Cover every name on your watchlist this earnings season.
Automations, AI chat, and live calls across 16,000+ companies.
Book demo

Next Pulse Biosciences earnings date

Logotype for Pulse Biosciences Inc
Q4 202618 Mar, 2027

AI chat

Ask anything. Verify everything.

Ask across every event and document from public companies. Each answer links back to the exact line in the transcript, slide or filing it came from.Learn more

Automations

Zero in on what matters

Define the prompt once. It runs the moment a company publishes or on a schedule you set. Outputs map to the exact signals you choose.Learn more

Live audio & transcripts

Be first

Join any earnings call live in one click, with no manual registration. Follow the transcript as it happens and jump straight to the moments that matter.Learn more

Quartr MCP connects your AI environment to 17K+ public companies

Pull live transcripts, filings, and slides into Claude or Codex via MCP. Combine Quartr's global IR data with any other dataset. Run agentic research and monitoring.
Included with Quartr Pro at no extra cost.Learn more

Quartr's AI stands out because it only pulls clean, first-party data from public companies. In investing, that's everything.

Jamie Ross

Investment Manager, GAM Investments

GAM
GAM

Research that used to take hours now takes seconds with Quartr Pro. Tracking shifts in tone or extracting tables, it's as simple as typing a query.

Tom O'Hara

Investment Director

Ciena
Ciena

Before Quartr we spent hours manually compiling insights through the peer earnings cycle. Now, these tasks are done faster, with greater precision.

Gregg Lampf

VP of Investor Relations

Frequently asked questions

Pulse Biosciences Inc. is a medical technology company that develops therapeutic devices based on its proprietary Nano-Pulse Stimulation (NPS) technology. This technology uses short, nanosecond-duration electrical pulses to treat cellular structures, offering potential applications in dermatology, oncology, and other medical fields. Pulse Biosciences' products are designed to provide non-invasive treatment options, with the goal of improving clinical outcomes for patients in various therapeutic areas. The company is headquartered in Hayward, California, and its shares are listed on the NASDAQ.